Apieron, Inc.

Apieron is developing a noninvasive monitor to measure exhaled nitric oxide for managing inflammation and controlling the underlying disease of asthma. Asthma is a chronic inflammatory disease of the airways in the lungs affecting more than 18 million people in the U.S. Controlling inflammation is the central focus for managing the underlying disease of asthma and regular use of anti-inflammatory medications is now the mainstay for treatment of symptoms. Nitric oxide has been shown to be a marker for inflammation and provides a means for monitoring the patient’s response to anti-inflammatory therapy. Clinical research strongly suggests that monitoring exhaled NO on a regular basis could significantly improve disease management.